Prices are closing data as of 2026-11-04, not real-time quotes. HK P/E and P/B multiples come from Eastmoney HK key statistics. Metric definitions: P/E, P/B, ROE.
Want the full AI research report for TIGERMED?
This free page compiles public filings, financial ratios and risk screening. Generate a full research report to add business moat & competition, valuation scenarios, catalysts and bull/bear cases right at this URL.
New users who sign up free and verify their email receive 2 free credits for research reports or professional valuation.
10-Year FinancialsFY2017–2025
Financial statements are reported in CNY, while share price and market cap are quoted in HKD.
Key Multi-Year Facts
- Revenue moved from CN¥1.68B in FY2017 to CN¥6.83B in FY2025 (8-year CAGR +19.1%).
- Profitable in every fiscal year across 2017–2025.
- Operating cash flow was below half of net income in FY2021.
Latest 5 Fiscal Years
| Fiscal Year | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue (CNY B) | 5.21 | 7.09 | 7.38 | 6.60 | 6.83 |
| YoY | 63.3% | 35.9% | 4.2% | -10.6% | 3.5% |
| Net Income (CNY B) | 2.88 | 2.02 | 2.02 | 0.41 | 0.89 |
| YoY | 64.4% | -30.0% | 0.4% | -80.0% | 119.2% |
| Operating Cash Flow (CNY B) | 1.16 | 1.13 | 1.15 | 1.10 | 1.12 |
| ROE | 16.8% | 10.7% | 10.0% | 1.9% | 4.3% |
| Gross Margin | 43.1% | 39.3% | 38.6% | 34.0% | 27.4% |
| Net Margin | 55.2% | 28.5% | 27.4% | 6.1% | 13.0% |
| Debt-to-Assets | 13.2% | 17.4% | 17.6% | 16.1% | 14.5% |
Show all 9 fiscal years
| Fiscal Year | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue (CNY B) | 1.68 | 2.30 | 2.80 | 3.19 | 5.21 | 7.09 | 7.38 | 6.60 | 6.83 |
| YoY | — | 36.7% | 21.9% | 13.9% | 63.3% | 35.9% | 4.2% | -10.6% | 3.5% |
| Net Income (CNY B) | 0.34 | 0.58 | 0.84 | 1.75 | 2.88 | 2.02 | 2.02 | 0.41 | 0.89 |
| YoY | — | 67.2% | 45.8% | 108.2% | 64.4% | -30.0% | 0.4% | -80.0% | 119.2% |
| Operating Cash Flow (CNY B) | 0.31 | 0.51 | 0.54 | 0.89 | 1.16 | 1.13 | 1.15 | 1.10 | 1.12 |
| ROE | 13.5% | 21.4% | 23.8% | 17.2% | 16.8% | 10.7% | 10.0% | 1.9% | 4.3% |
| Gross Margin | 42.4% | 42.7% | 46.1% | 47.1% | 43.1% | 39.3% | 38.6% | 34.0% | 27.4% |
| Net Margin | 20.5% | 25.1% | 30.0% | 54.9% | 55.2% | 28.5% | 27.4% | 6.1% | 13.0% |
| Debt-to-Assets | 22.6% | 28.7% | 27.0% | 8.4% | 13.2% | 17.4% | 17.6% | 16.1% | 14.5% |
Fiscal years follow the period-end calendar year (hover headers for period-end dates). ROE uses average beginning/ending equity. Source: HKEX / Eastmoney financial statements, compiled mechanically without AI. Official filings
Risk ChecklistAs of 2026-11-05
Rules-based screening using HK financial statements and HKEX announcement categories (no AI opinions).
Items Flagged for Review
- Watch
-
Watch
Profit WarningMaterial Events
An "Alert" or "Watch" item flags a number that merits verification in primary filings, not a sell signal.
Dividends
Trailing 12-month dividend: HK$0.145 per share, or 0.36% yield at closing price; last full fiscal year: HK$0.145 (payout ratio -27.0%).
Figures are gross HKD per share before applicable withholding or Stock Connect dividend taxes.
More data: All research reports · Sector leaders · Market hours & holidays.
Compiled mechanically from public filings and market quotes (data as of 2026-11-05). For informational purposes only, not investment advice.